MTOR and prostate carcinoma: For example, we found that the prognostic value of SOX9 [41] and mTOR expression [42] was limited to ERG-positive cancers while the prognostic value of NBS1 [43], SENP145 CD14746 only seen in ERG-negative prostate cancers.